Four approaches the new Congress should take to rein in prescription drug costs
The new Congress should with a renewed legislative effort rein in prescription drug costs by targeting antitrust abuses is the logical first step according to Michael A. Carrier. In Michael A. Carrier’s article appearing on www.healthaffairs.org, he suggests that the 117th Congress should focus on preventing four types of anticompetitive conduct which has bipartisan support, and most were included in bills that advanced during the last session. Read article here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org